Fig.01_IHC_anti-PSAFig.02_IHC_anti-PSAFig.03_IHC_anti-PSAFig.04_Multiplex_anti-PSAFig.05_Multiplex_anti-PSAFig.06_Multiplex_anti-PSA
  • SKU DIA-PSA
    Specificity

    PSA (KLK3)
    Species Reactivity

    Human
    Immunogen

    Recombinant peptide
    Host Species

    Mouse
    Isotype

    IgG1/l
    Clone

    HAM18
    Clonality (Mono-/Polyclonal)

    monoclonal
    Application

    ELISA, Immunohistochemistry (IHC), Immunohistochemistry (Paraffin-embedded Sections)
    Conjugation

    unconjugated
    Dilution

    Immunhistochemie (IHC): 1:100-1:800
    Format

    0.05% NaN3, 2% BSA, in PBS (pH 7.4), lyophilisate, purified antibody (from culture supernatant)
    Product line / Topic

    Enzymes, Tumor Marker / Biology
    Intended Use

    for Research Use Only
    Temperature - Storage

    2-8°C
    Temperature - Transport

    at room temperature
    Search Code

    DIAPSA, FFPE, Paraffin
    Manufacturer / Brand

    dianova
    Uniprot_ID

    P07288
    Gene_ID

    354
    Alias

    KLK3, Prostate Specific Antigen, PSA
  • HAM18 has been developed for detection of prostate specific antigen (PSA) in routine formalin-fixed paraffin-embedded prostate tissue specimen to be used in brightfield immunohistochemistry but also for multicolor immunofluorescence. HAM18 has been tested for sensitivity, specificity and prognostic significance on more than 20.000 tissues. Accordingly, HAM18 stands for being the best validated anti-PSA clone.

    Prostate Cancer is the most common cancer in men and PSA is the most important target for management of patients diagnosed with prostate cancer. PSA is a protease exclusively produced in prostate epithelial cells and secreted into the seminal fluid. Moreover, PSA reaches the blood stream and PSA levels have been shown to be proportional to quantity of prostate epithelial cells. Therefore serum analysis has developed the most commonly used method to detect PSA for prostate cancer prevention and to monitor response to therapy. Moreover, PSA immunohistochemistry is an important and common method for routine pathological diagnosis since it allows analysis of cellular expression profiles in prostate cancer.

    In diagnostic routine, PSA (HAM18) immunohistochemistry can be used in the following applications

    • Carcinoma of unknown origin: Rule out origin from a prostate cancer.
    • Bladder tumor of male patients without unequivocal urothelial precursor lesion suggesting urothelial origin: Rule out origin from a prostate cancer.
    • Advanced high-grade prostate cancer with rather low serum PSA levels: Low PSA expression in poorly differentiated cancer suggest that serum PSA levels may "underestimate" total tumor mass of the patient.
  • Fig.01_IHC_anti-PSA
    Fig.01_IHC_anti-PSA
    Fig.02_IHC_anti-PSA
    Fig.02_IHC_anti-PSA
    Fig.03_IHC_anti-PSA
    Fig.03_IHC_anti-PSA
    Fig.04_Multiplex_anti-PSA
    Fig.04_Multiplex_anti-PSA
    Fig.05_Multiplex_anti-PSA
    Fig.05_Multiplex_anti-PSA
    Fig.06_Multiplex_anti-PSA
    Fig.06_Multiplex_anti-PSA